ReviewMetabolites2023
High-Density Lipoprotein Alterations in Type 2 Diabetes and Obesity.
Review in Metabolites, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- The high-density lipoprotein lipidome in metabolic syndrome: A systematic review.European journal of clinical investigation · 2026Pooled it
- Prognostic impact of the combined effects of lipoprotein(a) and homocysteine in patients with premature myocardial infarction: a prospective cohort study.Frontiers in nutrition · 2026Article
- Clinical predictors of tocilizumab response in moderate-to-severe thyroid eye disease: a large single-center retrospective cohort study.Frontiers in endocrinology · 2026Article
- Peripheral inflammatory markers and clinical phenotypes reflecting the impact of diabetes on Parkinson's disease.Journal of Parkinson's disease · 2025Article
- High-density lipoproteins, Part 1. Epidemiology, antiatherogenic effects, and therapies designed to increase their serum levels.American journal of preventive cardiology · 2025Review
- Cholesterol and triglyceride concentrations following 12-18 months of clinically prescribed elexacaftor-tezacaftor-ivacaftor-PROMISE sub-study.Journal of clinical & translational endocrinology · 2025Article
- Elevated high-density lipoprotein triglycerides increase atherosclerotic risk.Journal of lipid research · 2025Article
- High-Density Lipoprotein Lipid and Protein Cargo and Cholesterol Efflux Capacity Before and After Bariatric Surgery.Arteriosclerosis, thrombosis, and vascular biology · 2025Observational
- Association Between CTLA4 Level and Obesity, Dyslipidemia, and Type 2 Diabetes Mellitus.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2025Article
- The nonlinear relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol and the risk of diabetic kidney disease in patients with type 2 diabetes mellitus.Frontiers in medicine · 2025Article
- U-shaped association of uric acid to HDL cholesterol ratio (UHR) with ALL-cause and cardiovascular mortality in diabetic patients: NHANES 1999-2018.BMC cardiovascular disorders · 2024Article
- Patterns of Lipid Abnormalities in Obesity: A Comparative Analysis in Normoglycemic and Prediabetic Obese Individuals.Journal of personalized medicine · 2024Article
- Platelet/High-Density Lipoprotein Ratio (PHR) Predicts Type 2 Diabetes in Obese Patients: A Retrospective Study.Healthcare (Basel, Switzerland) · 2024Article
- High-Density Lipoprotein Modifications: Causes and Functional Consequences in Type 2 Diabetes Mellitus.Cells · 2024Review
- Acute myocardial infarction preferentially alters low-abundant, long-chain unsaturated phospholipid and sphingolipid species in plasma high-density lipoprotein subpopulations.Atherosclerosis plus · 2024Article
- Decoding cardiovascular risks: analyzing type 2 diabetes mellitus and ASCVD gene expression.Frontiers in endocrinology · 2024Article
- Anthropometric and Biochemical Correlations of Insulin Resistance in a Middle-Aged Maltese Caucasian Population.Journal of nutrition and metabolism · 2024Article
- Oxysterols in Vascular Cells and Role in Atherosclerosis.Advances in experimental medicine and biology · 2024Article
- Antioxidant and Anti-Inflammatory Functions of High-Density Lipoprotein in Type 1 and Type 2 Diabetes.Antioxidants (Basel, Switzerland) · 2023Review
- Healthy lifestyle linked to innate immunity and lipoprotein metabolism: a cross-sectional comparison using untargeted proteomics.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alterations affecting high-density lipoproteins (HDLs) are one of the various abnormalities observed in dyslipidemia in type 2 diabetes mellitus (T2DM) and obesity. Kinetic studies have demonstrated that the catabolism of HDL particles is accelerated. Both the size and the lipidome and proteome of HDL particles are significantly modified, which likely contributes to some of the functional defects of HDLs. Studies on cholesterol efflux capacity have yielded heterogeneous results, ranging from a defect to an improvement. Several studies indicate that HDLs are less able to inhibit the nuclear factor kappa-B (NF-κB) proinflammatory pathway, and subsequently, the adhesion of monocytes on endothelium and their recruitment into the subendothelial space. In addition, the antioxidative function of HDL particles is diminished, thus facilitating the deleterious effects of oxidized low-density lipoproteins on vasculature. Lastly, the HDL-induced activation of endothelial nitric oxide synthase is less effective in T2DM and metabolic syndrome, contributing to several HDL functional defects, such as an impaired capacity to promote vasodilatation and endothelium repair, and difficulty counteracting the production of reactive oxygen species and inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.